<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref62">
 <mixed-citation publication-type="journal" id="cit62">
  <name>
   <surname>Lin</surname>
   <given-names>C.-K.</given-names>
  </name>; 
  <name>
   <surname>Bai</surname>
   <given-names>M.-Y.</given-names>
  </name>; 
  <name>
   <surname>Hu</surname>
   <given-names>T.-M.</given-names>
  </name>; 
  <name>
   <surname>Wang</surname>
   <given-names>Y.-C.</given-names>
  </name>; 
  <name>
   <surname>Chao</surname>
   <given-names>T.-K.</given-names>
  </name>; 
  <name>
   <surname>Weng</surname>
   <given-names>S.-J.</given-names>
  </name>; 
  <name>
   <surname>Huang</surname>
   <given-names>R.-L.</given-names>
  </name>; 
  <name>
   <surname>Su</surname>
   <given-names>P.-H.</given-names>
  </name>; 
  <name>
   <surname>Lai</surname>
   <given-names>H.-C.</given-names>
  </name> (
  <year>2016</year>) 
  <article-title>Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer</article-title>. 
  <source>Oncotarget.</source>
  <volume>7</volume>, 
  <fpage>8993</fpage>â€“
  <lpage>9006</lpage>. 
  <pub-id pub-id-type="doi">10.18632/oncotarget.7113</pub-id>.
  <pub-id pub-id-type="pmid">26848771</pub-id>
 </mixed-citation>
</ref>
